The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Sep. 17, 2020
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

The Children's Medical Center Corporation, Boston, MA (US);

Inventors:

Minglin Ma, Ithaca, NY (US);

Daniel G. Anderson, Framingham, MA (US);

Robert S. Langer, Newton, MA (US);

Omid Veiseh, Bellaire, TX (US);

Joshua Charles Doloff, Quincy, MA (US);

Delai Chen, Woburn, MA (US);

Christian J. Kastrup, Bowen Island, CA;

Arturo Jose Vegas, Belmont, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 35/39 (2015.01); A61K 9/50 (2006.01); B01J 13/04 (2006.01); A61K 45/06 (2006.01); A61K 35/12 (2015.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0024 (2013.01); A61K 9/5036 (2013.01); A61K 9/5078 (2013.01); A61K 9/5089 (2013.01); A61K 35/39 (2013.01); A61K 45/06 (2013.01); B01J 13/046 (2013.01); A61K 9/4833 (2013.01); A61K 9/4866 (2013.01); A61K 2035/126 (2013.01); A61K 2035/128 (2013.01);
Abstract

Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.


Find Patent Forward Citations

Loading…